## **Comprehensive and Diversified Monoclonal Antibody Pipeline**

	Product (Reference Drug)	Target	Indication	Pre-Clinical	IND	Phase 1	Phase 2 <sup>®</sup>	Phase 3	NDA
Biosimilar Portfolio	HLX01 (MabThera)	CD20	NHL <sup>(2)</sup>	First Chinese B	liosimilar Approved ac	cording to the Biosimi	ilar Guideline		
	HLX02 (Herceptin)	HER2	BC/mGC <sup>(4)</sup>	NDA accepted	by NMPA and EMA				
	HLX03 (Humira)	TNF-α	PS/RA/AS <sup>(7)</sup>	NDA accepted	by NMPA				
	HLX04 (Avastin )	VEGF	mCRC/nsNSCLC <sup>(8)</sup>						
	HLX05 (Erbitux) <sup>(9)</sup>	EGFR	mCRC/SCCHN				•		
	HLX12 (Cyramza)	VEGFR2	Solid Tumors <sup>(10)</sup>						
	HLX11 (Perjeta )	HER2	BC						
	HLX13 (Yervoy)	CTLA-4	Solid Tumors						
	HLX14 (xgeva )	RANKL	Solid Tumors						
	HLX15 (Darzalex)	CD-38	Multiple Myeloma						
Bio- innovative Portfolio	HLX01	CD20	RA <sup>(11)</sup>						
	HLX07	EGFR	Solid Tumors						
	HLX10	PD-1	Solid Tumors						
	HLX20	PD-L1	Solid Tumors						
	HLX06	VEGFR2	Solid Tumors						
	HLX04	VEGF	wAMD/DR (11)						
	HLX22	HER2	Solid Tumors				<b>•</b>		
	HLX55	cMET	Solid Tumors						
	HLX58	Claudin18.2	Solid Tumors						
	HLX09	CTLA4	Solid Tumors						
	HLX23	CD73	Solid Tumors						
	HLX24	CD47	Solid Tumors						
	HLX26	LAG3	Solid Tumors						
	HLX59	CD27	Solid Tumors						
	HLX51	OX40	Solid Tumors						
	HLX52	TIM-3	Solid Tumors						
	HLX53	TIGIT	Solid Tumors						
	HLX63	GPC3	Solid Tumors						
	HLX56	DR	Solid Tumors						
Combo Therapy	HLX04 <sup>(13)</sup> +HLX10	VEGF+PD-1	nsNSCLC					•	
	HLX04 <sup>(13)</sup> +HLX10	VEGF+PD-1	HCC						
	HLX07+HLX10	EGFR+PD-1	SCCHN						
	HLX10 <sup>(13)</sup> +Chemo	PD-1	mESCC						
			sqNSCLC						
			SCLC					<u> </u>	

- Our Phase 3 clinical trial for HLX01 focused on the treatment of CD20-positive diffuse large B cell lymphoma, which is the most common subtype of NHL. HLX01's reference drug, MabThera, is approved in China for three NHL subtypes (namely DLBCL, relapsed or refractory follicular central lymphoma and previously-untreated CD20-positive stage III-IV follicular lymphoma). HLX01 is also approved for these three indications.
- Argentina, Paraguay, Uruguay and Bolivia. Our Phase 3 clinical trial for HLX02 focuses on the treatment of HER2+ metastatic breast cancer. As HLX02's 10. reference drug, Herceptin, is approved in China for HER2+ early breast cancer, HER2+ metastatic breast cancer and 11. HER2+ metastatic gastric cancer, our NDA in China seeks approval for all three indications for HLX02. Our commercialization partner Accord filed an MAA with the 12. EMA for these three indications and gastroesophageal junction cancer, Subject enrolment of the Phase 3 clinical 13. trial for HLX02 has been completed. While HLX02 is still undergoing Phase 3 clinical trial, our NDA for HLX02 was accepted by the NMPA in April 2019 and is currently under its priority review.
- Over 70 jurisdictions and regions in Europe, MENA and CIS.
- Australia, New Zealand, Colombia and Malaysia. Our Phase 3 clinical trial for HLX03 focuses on the treatment of plaque psoriasis. As HLX03's reference d Humira, is approved in China for plaque psoriasis pecific

Targets

filed for NDA approval for all three indications for HLX03. We have completed the Phase 3 clinical trial for HLX03. Our NDA for HLX03 was accepted by the NMPA in January 2019 and is currently under its priority review. Our Phase 3 clinical trial for HLX04 focuses on the treatment of mCRC. As HLX04's reference drug, Avastin, is approved in China for mCRC and unresectable, locally advanced, recurrent or metastatic nsNSCLC, we plan to seek NDA approval for both indications for HLX04.

Licensed out to Shanghai Jingze. Includes advanced gastric cancer, gastroesophageal junction adenocarcinoma, NSCLC and mCRC. Considered a bio-innovative product because the originator product has not been approved for the relevant indication

Greater China and certain countries in Southeast, Central and South Asia.

rheumatoid arthritis and ankylosing spondylitis, we have

We do not consider HLX07, HLX10, HLX04 + HLX10 combination therapy and HLX10 + Chemo combination therapy to be our Core Products as (i) data on Phase 1 clinical trials for HLX07, HLX10 and HLX04 + HLX10 combination therapy have not become available, and (ii) data on Phase 3 clinical trials for HLX10 + Chemo, which do not require Phase 1 clinical trials, have not become available. We are also developing HLX10 to treat Hepatitis

Angiogenesis **Targets** 

Immuonotherapeutic Targets

> Combo Therapy

> > Others











## **Henlius Differentiation Highlights**

1

Fully-Integrated & Efficient Global R&D Platforms

- ✓ In-house R&D Platforms
  Covering Whole Processes
- ✓ Global Synergy of 3 R&D sites
- √ Fast-follow de-risk strategy
- √ \$220M high-efficient R&D investment

2

Capable to Enter
Global Main
Regulatory Markets

- ✓ International Quality Standard
- ✓ Strong RA & Clinical Medical Team
- √ 31 INDs obtained across six jurisdictions

3

Market Penetration
Speed

- √ 6 Blockbusters go to market in 3 years
- √ 3-4 products will be first-entry to Chinese markets

4

Fosun/Fosun pharma's Support

- R&D Capital investment
- ✓ Market Access & Sales resources
- ✓ Government Affairs
- ✓ Synergy in Strategy and Culture

5

High-level Expert Team

- ✓ Sr. Management Team hold 20+y of industry experiences covering entire value-chains
- √ 79 senior industry experts
  - **67%** 10+y of Industry Experiences
- **62%** Oversea Experiences